Cancer Vaccines in Ovarian Cancer: How Can We Improve?-Reference-Cited by-同舟云学术

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Published:2016-05-03 Issue:2 Volume:4 Page:10
ISSN:2227-9059
Container-title:Biomedicines
language:en
Short-container-title:Biomedicines

Author:

Martin Lluesma Silvia,Wolfer Anita,Harari Alexandre^ORCID,Kandalaft Lana

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Link

http://www.mdpi.com/2227-9059/4/2/10/pdf

Reference173 articles.

1. Ovarian Cancer: Statisticshttp://www.cancer.net/cancer-types/ovarian-cancer/statistics

2. GLOBOCAN 2012http://globocan.iarc.fr/old/burden.asp?selection_pop=224900&Text-p=World&selection_cancer=22182&Text-c=Ovary&pYear=8&type=0&window=1&submit=%C2%A0Execute

3. Rethinking ovarian cancer: recommendations for improving outcomes

4. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

5. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients;Schlienger;Clin. Cancer Res.,2003

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics;Frontiers in Oncology;2024-05-30

2. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer;Critical Reviews in Oncology/Hematology;2024-02

3. Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial;Clinical Cancer Research;2023-05-01

4. The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer;Biomolecules;2023-01-12

5. Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer;Pharmaceutical Research;2022-11-14